Kadmon begins Phase IIa Portion of KD020 study

Kadmon has started the Phase IIa portion of a Phase Ib/IIa study of KD020 in autosomal dominant polycystic kidney disease (ADPKD), following unanimous recommendation of the study's data safety committee.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news